Elsevier

Cancer Treatment Reviews

Volume 38, Issue 5, August 2012, Pages 554-558
Cancer Treatment Reviews

General and Supportive Care
Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials

https://doi.org/10.1016/j.ctrv.2011.07.002Get rights and content

Abstract

Background

Health-related quality of life (HRQOL) parameters are often used as end points in phase III trials in advanced breast cancer. The frequency and correlates of significant gains in HRQOL have not been assessed.

Methods

To evaluate the contemporary role for HRQOL assessment in advanced breast cancer, we searched PubMed for the main and companion papers reporting the results of phase III trials on systemic antineoplastic therapies published between 1/98 and 7/09 in 11 leading journals.

Results

The search yielded 87 trials that enrolled a total of 33,669 patients. HRQOL was mentioned/reported in the main paper in 34 trials, reported in a companion paper in one (a total of 35/87 = 40%), and mentioned in the abstract of the main paper in 19/34 cases (56%). There was no temporal trend for reporting on HRQOL in the two 6-year periods. Although formal statistical comparisons were reported in 31/35 cases (89%), a significant difference was found in only 4/31 (13%) trials, always favoring the experimental arm. Given the small number of studies with a significant HRQOL finding, we could not assess correlates of gain in HRQOL.

Conclusions

HRQOL is one of the key indicators of treatment benefit in advanced breast cancer, but contemporary systemic therapies in this setting do not appear to affect HRQOL differentially.

Introduction

With nearly 1.3 million new cases and almost half a million deaths annually, breast cancer is among the most important health problems, especially in developed nations.1 Breast cancer mortality in the western world has decreased over the last decade as a consequence of the wider use of screening mammography and more effective adjuvant therapy.2 Even though hormone therapy, chemotherapy, and HER-2 targeted therapy are able to decrease the risk of disease relapse in early-stage breast cancer, treatment failure occurs in a substantial number of patients, and the median survival for metastatic breast cancer remains in the range of mere 2 to 3 years.3, 4, 5 The management of advanced breast cancer is thus a major clinical challenge for medical oncologists. Since cure for this disease remains elusive for most patients, the chief therapeutic goal is palliation aiming at prolongation of survival with good quality of life and symptom control.6

During the past decades, health care has progressively shifted its focus solely from the disease process to include patient well-being and health-related quality of life (HRQOL) as important outcomes,7 particularly in medical oncology.8 The use of HRQOL data to help guide selection of optimal treatment is best addressed in the context of randomized controlled trials.9 The primary objective of randomized controlled trials in medical oncology is generally related to the efficacy of interventions. Nevertheless, more attention has recently been paid to improving the way patients live during cancer treatment.10, 11 As a result, HRQOL assessment has become an important secondary objective in cancer clinical trials, including those in breast cancer.9, 12, 13, 14

Although HRQOL assessment has many potential utilities and implications for clinical practice and research, the role of HRQOL data to help the selection of therapy for breast cancer is still unclear. A few years ago, Goodwin et al.9 examined 20 trials in advanced breast cancer that were published between 1987 and 2001 and in which HRQOL had been assessed. These authors found that HRQOL assessment in those studies provided little additional information beyond that obtained from traditional medical outcomes, leading them to state that “the routine use of HRQOL measurement in randomized drug trials in metastatic breast cancer may not be warranted unless one or more of the agents being tested has very modest or differing toxicities that could have an effect on HRQOL”. Even though HRQOL parameters are often used as end points in phase III trials of systemic therapy for advanced breast cancer, the extent to which this has been done in recent studies, and the frequency and correlates of significant gains in HRQOL, have not been systematically assessed. In the current study, our objective was to analyze HRQOL results in phase III trials reported over the past 12 years, in an attempt to evaluate the contemporary role for HRQOL assessment in advanced breast cancer.

Section snippets

Search strategy

In previous studies, we have looked at various aspects concerning the use of end points in the recent literature on advanced breast cancer.5, 15 In brief, our trial selection criteria consisted in using PubMed and the medical subject headings “breast neoplasms” and “drug therapy” to search for the main paper reporting the efficacy results of phase III trials on systemic antineoplastic therapies published between January 1, 1998, and July 15, 2009 in 11 leading journals (Annals of Oncology,

Characteristics of the phase III trials

The search identified 87 phase III trials that were eligible for analysis (a complete list of the trials is available upon request). Such trials enrolled a total of 33,669 evaluable patients in 192 trial arms. Two of these arms, one in each trial, consisted of the use of placebo or best supportive care alone as maintenance after patients had achieved disease stability or a partial response to first-line therapy. Except for 10 trials with three arms, two factorial trials with four arms each, and

Discussion

The current study shows that HRQOL end points have been used in approximately 40% of contemporary phase III trials in advanced breast cancer. In most of the trials in which such end points were used, formal HRQOL statistical comparisons between groups were undertaken. However, significant differences between groups were found in only four of 31 trials (13%). Of note, in one of these studies HRQOL assessment was part of a composite end point in which ‘gain from treatment’ was evaluated.37 We

Disclosures

The authors have declared no conflicts of interest.

Acknowledgment

The authors wish to thank Prof. Neil Aaronson for his helpful discussions of the manuscript.

References (59)

  • C. Bernard-Marty et al.

    Facts and controversies in systemic treatment of metastatic breast cancer

    Oncologist

    (2004)
  • E.D. Saad et al.

    Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

    J Clin Oncol

    (2010)
  • S. Greenfield et al.

    Recent developments and future issues in the use of health status assessment measures in clinical settings

    Med Care

    (1992)
  • M. Michael et al.

    Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment

    CMAJ

    (1998)
  • P.J. Goodwin et al.

    Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock

    J Natl Cancer Inst

    (2003)
  • L.M. Minasian et al.

    Health-related quality of life and symptom management research sponsored by the National Cancer Institute

    J Clin Oncol

    (2007)
  • A. Bottomley et al.

    International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience

    J Clin Oncol

    (2007)
  • J. Mandelblatt et al.

    Descriptive review of the literature on breast cancer outcomes: 1990 through 2000

    J Natl Cancer Inst Monogr

    (1990)
  • A. Montazeri

    Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007

    J Exp Clin Cancer Res

    (2008)
  • A. Berruti et al.

    Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

    J Clin Oncol

    (2002)
  • A.D. Seidman et al.

    Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840

    J Clin Oncol

    (2008)
  • S. Chan et al.

    Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

    J Clin Oncol

    (2009)
  • K.S. Albain et al.

    Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

    J Clin Oncol

    (2008)
  • S. Chia et al.

    Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT

    J Clin Oncol

    (2008)
  • P.A. Cassier et al.

    A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

    Breast Cancer Res Treat

    (2008)
  • K. Miller et al.

    Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

    N Engl J Med

    (2007)
  • A. Gennari et al.

    Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer

    J Clin Oncol

    (2006)
  • W.J. Gradishar et al.

    Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer

    J Clin Oncol

    (2005)
  • S.E. Jones et al.

    Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

    J Clin Oncol

    (2005)
  • Cited by (22)

    • Testing the effects of the Strong Together self-advocacy serious game among women with advanced cancer: Protocol for the STRONG randomized clinical trial

      2023, Contemporary Clinical Trials
      Citation Excerpt :

      When patients lack the skills to advocate for themselves, they experience higher symptom burden, lower quality of life, and sub-optimal use of healthcare services [5–8]. Female patients with cancer are at risk for poor health outcomes because of gender differences in the prevalence and severity of symptoms [9,10], their preferences for care delivery [11], and the ways in which they communicate with healthcare providers [12]. Patients with breast or gynecological cancers in particular have a high prevalence of advanced-stage disease, report high rates of symptom burden, and face unclear treatment decisions compared to other cancer types [13–16].

    • Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

      2017, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      They observed that HRQoL was assessed in almost 60% of phase III studies, accounting for 72 out of 122 extracted studies in advanced NSCLC published between January 1998 and December 2009 (Saad et al., 2012). A growing interest for HRQoL can also be observed in adjuvant therapeutic settings, such as chemotherapy in breast cancer or hormone therapy in prostate cancer (Adamowicz et al., 2012; Penson et al., 2003). The role of adjuvant treatment in preventing or delaying recurrence after primary therapy and its potential early and delayed impact on HRQoL plays an important role in therapeutic decision-making.

    • Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer

      2016, Cancer Treatment Reviews
      Citation Excerpt :

      Of the 32 trials with only active comparators, for which HRQOL parameters were formally compared, 12 (38%) found a significant difference, three of which favoring the experimental arm (P = 0.63 for the comparison between trials with and without a BSC-alone arm). We showed that HRQOL as an endpoint was used in about 36% of recent CRC phase III trials, a proportion that is similar to the one we previously found in advanced breast cancer (40%) and lower than in non-small-cell lung cancer (NSCLC) trials (59%) [54,55]. Significant HRQOL differences between study arms were found in 39% of CRC trials that formally compared this endpoint between arms.

    • Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

      2016, The Lancet Oncology
      Citation Excerpt :

      Specific recommendations fall beyond the scope of our paper but several key initiatives, such as the Setting International Standards of Analyses of Quality Of Life in cancer clinical trials are expected to help remedy this problem. We also noted that currently available instruments to measure HRQOL in advanced breast cancer are not well attuned to detect plausible differences between newer competing therapies regarding their differential effects.78,79 Targeted therapies are initially tested in patients with metastatic cancer, but the range of their side-effects is not covered by the two main tools, EORTC-BR23 and FACT-B, developed many years ago.

    View all citing articles on Scopus
    View full text